AstraZeneca's Imfinzi/Imjudo Combo Shows Sustained Overall Survival Benefit At Four Years In Liver Cancer
Portfolio Pulse from Vandana Singh
AstraZeneca has released updated results from the HIMALAYA Phase 3 trial evaluating Imfinzi plus Imjudo in unresectable hepatocellular carcinoma patients. The data shows that the treatment reduced the risk of death by 22% compared to Bayer's Nexavar. The safety profile was consistent with known profiles and no new safety signals were observed. AstraZeneca's shares are down 0.16% at $70.85.
June 29, 2023 | 5:41 pm
News sentiment analysis
Sort by:
Descending
POSITIVE IMPACT
AstraZeneca's Imfinzi plus Imjudo shows positive results in Phase 3 trial, reducing death risk in liver cancer patients.
The positive results from the Phase 3 trial of AstraZeneca's Imfinzi plus Imjudo could potentially boost the company's stock in the short term. However, the slight decrease in the company's stock price indicates that the market may have already priced in this information.
CONFIDENCE 90
IMPORTANCE 80
RELEVANCE 100
NEGATIVE IMPACT
AstraZeneca's Imfinzi plus Imjudo shows better results than Bayer's Nexavar in Phase 3 trial.
The news that AstraZeneca's Imfinzi plus Imjudo outperforms Bayer's Nexavar in a Phase 3 trial could potentially have a negative impact on Bayer's stock in the short term.
CONFIDENCE 80
IMPORTANCE 60
RELEVANCE 50